ANDA 214654, held by Yichang Humanwell Pharmaceutical. Venlafaxine Hydrochloride.
As of Nov 21, 2026, ANDA 214654 (Venlafaxine Hydrochloride), held by Yichang Humanwell Pharmaceutical, was first approved by FDA on Aug 6, 2021, with 6 approved supplements and 0 published complete response letters.
Venlafaxine Hydrochloride Extended-Release Capsules, USP are indicated in adults for the treatment of: Major Depressive Disorder (MDD) Generalized Anxiety Disorder (GAD) Social Anxiety Disorder (SAD) Panic Disorder (PD) Venlafaxine hydrochloride extended-release capsules are a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of adults with: Major Depressive Disorder (MDD) Generalized Anxiety Disorder (GAD) Social Anxiety Disorder (SAD) Panic Disorder (PD)
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 6, 2021 | Original application | Approved | None posted |
| Venlafaxine HydrochlorideEQ 37.5MG BASE · capsule, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 75MG BASE · capsule, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 150MG BASE · capsule, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Sep 17, 2025 | Supplement 22Labeling · Standard review | Approved | None posted |
| Jan 30, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jan 30, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 30, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jan 30, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jan 30, 2024 | Supplement 14Labeling · Standard review | Approved | None posted |
| Aug 6, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters